

**Intervacc announces changes in the Nomination Committee**

**Stockholm, December 21, 2023 – Intervacc AB (publ) announces that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden have resigned from the Nomination Committee.**

**For more information please contact:**

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: [jonas.sohlman@intervacc.se](mailto:jonas.sohlman@intervacc.se)

*The information was submitted for publication, through the agency of the contact person set out above on December 21, 2023, 08.30 a.m. CET.*

**About Intervacc**

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

**Contact information for Certified Adviser**

Eminova Fondkommission AB

E-mail: [adviser@eminova.se](mailto:adviser@eminova.se), Phone: +46 (0)8 – 684 211 10